About Us

Working towards insulin free T1D

Who We Are

The UK Type 1 Diabetes Research Consortium (UK T1D-RC) was set up in 2015 with major funding from Diabetes UK & the JDRF, to promote, develop and support immunotherapy research in T1D.

Since then, a network of 30 Research Sites has been established throughout the UK to recruit children and adults into clinical trials of new immunotherapy treatments in T1D, monitoring studies and also screening for T1D.

There are 2 main cores to UK T1D, a clinical engagement & training core (CET) led by Prof Colin Dayan from Cardiff University and a mechanistic core of 8 specialist Labs located throughout the UK, led by Tim Tree from Kings College, London.

T1D UK Members in Cardiff

24/02/2017 – University Hospital of Wales, Cardiff

Our Partners

Our Collaborators

Principal Aim

The goal of the UK T1D Research Consortium is to benefit people with T1D or at risk of getting T1D by speeding up the process to finding new treatments to preserve beta cell function in Type 1 Diabetes, “moving towards insulin-free T1D.”

The Vision

An improved environment for T1D research in the UK including immune therapy trials, monitoring studies and screening: rapid, early and enhanced patient recruitment; enhanced academic engagement with trial design; the provision of a mechanistic core.

The Clinical Engagement & Training Core

The aim of the CET team is to support recruitment into immune therapy trials. The team will co-ordinate and promote trials to Research Sites, engage with teams at the sites and develop and deliver a training programme for research and clinical teams at sites.

Mechanistic Core

The mechanistic core brings together experts in the immunology of T1D from 8 different labs across the UK: Bristol, Cambridge, Cardiff, Exeter, Oxford, King’s College London, Queen Mary’s London & Swansea. These laboratories will provide state of the art immunological assays that will study the impact of immune therapy trials, investigating exactly how different treatments work to control the immune attack that causes type 1 diabetes and working out if it is possible to predict who will benefit from each treatment.